Drugs / P2B001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03329508 | Jan 2018 → Aug 2021 | Parkinson disease | Pharma Two B Ltd. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P2B001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03329508 ↗ |
| Route | Oral | “Subjects will be requested to take one capsule and 1-3 tablets of study drug by mouth with a glass of water every day for 13 weeks.” NCT03329508 ↗ |